Web Desc
Hemorrhagic Fever Viruses
Organizer(s): William E. Dowling and Thomas W. Geisbert
Date: December 04 - 08, 2016
Location: Hilton Santa Fe Historic Plaza Hotel, Santa Fe, NM, USA
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Viral Hemorrhagic Fevers (VHF) are caused by a disparate group of viruses from four different virus families – Arenaviruses, Bunyaviruses, Filoviruses and Flaviviruses. These viruses have a substantial public health impact with few effective vaccines or antivirals available. Although their structures, vectors and replication cycles are very different, there are common pathogenic features between them. The meeting is designed to bring together the research communities around these individual viral families, to explore common pathways and mechanisms employed by the viruses, to discuss current medical countermeasures, and to foster collaborations. The specific aims of the conference are to: 1) Discuss the methods employed by hemorrhagic fever viruses to subvert host innate immune responses; 2) Assess the mechanisms causing endothelial dysfunction and coagulopathy that are hallmarks of VHF disease; 3) Look at the contributions of host genetics in disease progression; 4) Describe the state of the art in diagnostics; and 5) Present data on promising candidate vaccines and therapeutics. This symposium will occupy a unique niche as there is not a current scientific conference which brings these communities together in a focused manner.
Global Health Travel Award Deadline: July 19 2016
Scholarship Deadline: August 4 2016
Discounted Abstract Deadline: August 4 2016
Abstract Deadline: September 12 2016
Discounted Registration Deadline: October 4 2016
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Bill & Melinda Gates Foundation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Mapp Biopharmaceutical, Inc.

Merck Vaccine Division
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI126804-01
Funding for this conference was made possible (in part) by 1 R13 AI 126804 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, December 04 | 4:00PM - 8:00PM
Arrival and Registration
Room: Promenade


Sunday, December 04 | 6:00PM - 8:00PM
Welcome Mixer
Room: Promenade
No registration fees are used to fund alcohol served at this function.

Monday, December 05 | 7:30AM - 8:30AM
Breakfast
Room: Pecos/Canyon


Monday, December 05 | 8:30AM - 9:30AM
Welcome and Keynote Address
Room: Mesa A-B

Speaker 1 of 3
* William E. Dowling, Coalition for Epidemic Preparedness Innovations, USA

Monday, December 05 | 8:30AM - 9:30AM
Welcome and Keynote Address
Room: Mesa A-B

Speaker 2 of 3
* Thomas W. Geisbert, University of Texas Medical Branch, USA

Monday, December 05 | 8:30AM - 9:30AM
Welcome and Keynote Address
Room: Mesa A-B

Speaker 3 of 3
Erica Ollmann Saphire, La Jolla Institute for Immunology, USA
The Molecular Tool-Kit of Hemorrhagic Fever Viruses

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B

Speaker 1 of 6
* Erica Ollmann Saphire, La Jolla Institute for Immunology, USA

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B

Speaker 2 of 6
Christopher F. Basler, Georgia State University, USA
Ebola Virus VP35 and VP24 are Innate Immune Suppressors and Virulence Determinants

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B


Coffee Break

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B

Speaker 4 of 6
Elke Mühlberger, Boston University, USA
Silence Is Golden – Distinct Host Responses in Human Macrophages Infected with High or Low Pathogenic Ebolaviruses

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B

Speaker 5 of 6
Juan Carlos de la Torre, The Scripps Research Institute, USA
Novel Strategies to Developing Therapeutics and Vaccines to Combat Hemorrhagic Fever Arenaviruses

Monday, December 05 | 9:30AM - 12:15PM
Innate Immune Evasion I
Room: Mesa A-B

Speaker 6 of 6
Ana Fernandez-Sesma, Icahn School of Medicine at Mount Sinai, USA
Modulation of Innate Immunity by Dengue Virus

Monday, December 05 | 12:15PM - 2:30PM
On Own for Lunch


Monday, December 05 | 12:15PM - 1:00PM
Poster Setup
Room: Mesa C


Monday, December 05 | 1:00PM - 10:00PM
Poster Viewing
Room: Mesa C


Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 1 of 8
* Christopher F. Basler, Georgia State University, USA

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 2 of 8
Gaya K. Amarasinghe, Washington University in St. Louis, USA
Role of Ebola Viral VP24 Protein in Immune Evasion

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 3 of 8
Hinh Ly, University of Minnesota, Twin Cities, USA
Molecular Mechanisms of Inhibition of Antigen-Presenting Cells by Human Hemorrhagic Fever-Causing Arenaviruses

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 4 of 8
Colm Atkins, University of Texas Medical Branch, USA
Rift Valley Fever Virus Infection in Human Neuronal Cells

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 5 of 8
Daniel Stephen Chertow, National Institutes of Health, USA
Role of Ebola Virus Proteins in Bystander Lymphocyte Apoptosis

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 6 of 8
Lilia Melnik, Tulane University, USA
The Ebola Virus Delta-Peptide Has Viroporin-Like Activity

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 7 of 8
Jessica R. Spengler, Centers for Disease Control and Prevention, USA
Crimean-Congo Hemorrhagic Fever Virus Strain-Dependent Disease in Humanized Mice

Monday, December 05 | 2:30PM - 4:30PM
Workshop 1: Innate Immune Evasion II
Room: Mesa A-B

Speaker 8 of 8
Emily Speranza, Boston University, USA
Delineating Survival from Fatal Outcome in Ebola Virus Disease in Humans

Monday, December 05 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Monday, December 05 | 5:00PM - 7:00PM
Host Genetics
Room: Mesa A-B

Speaker 1 of 3
* Cesar Muñoz Fontela, Heinrich Pette Institute, Germany
Dissecting Human Immunity to Ebola Virus

Monday, December 05 | 5:00PM - 7:00PM
Host Genetics
Room: Mesa A-B

Speaker 2 of 3
Jan E. Carette, Stanford University, USA
Host Factors Involved in Pathogenesis of HFV

Monday, December 05 | 5:00PM - 7:00PM
Host Genetics
Room: Mesa A-B

Speaker 3 of 3
Beatriz de la Caridad Sierra Vázquez, Pedro Kouri Institute for Tropical Medicine, PAHO/WHO Collaborating Center, Cuba
Short Talk: Lipid/Cholesterol Metabolism Involved in Viral Replication and Immune Response Provide African-Ancestry Protection Against Dengue Hemorrhagic

Monday, December 05 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pecos/Canyon
No registration fees are used to fund alcohol served at this function.

Monday, December 05 | 7:30PM - 10:00PM
Poster Session 1
Room: Mesa C


Tuesday, December 06 | 7:30AM - 8:30AM
Breakfast
Room: Pecos/Canyon


Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B

Speaker 1 of 6
* Nigel Mackman, University of North Carolina at Chapel Hill, USA
Coagulation Cascade Activation during Viral Infection

Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B

Speaker 2 of 6
Lisa E. Hensley, NIAID, National Institutes of Health, USA
Late-Stage Filovirus Disease in NHPs

Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B


Coffee Break

Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B

Speaker 4 of 6
Anita K. McElroy, Emory University, USA
Endothelial Dysfunction and Coagulopathy during Ebola Virus Disease in Humans

Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B

Speaker 5 of 6
Stefan Kunz, Lausanne University Hospital, Switzerland
Molecular Mechanisms underlying Lassa Virus Invasion of Vascular Endothelial Cells

Tuesday, December 06 | 8:30AM - 11:45AM
Endothelial Dysfunction and Coagulopathy I
Room: Mesa A-B

Speaker 6 of 6
Dennis A. Bente, University of Texas Medical Branch, USA
Crimean-Congo Hemorrhagic Fever Virus in of the Transmission and Pathogenesis: Current Considerations

Tuesday, December 06 | 11:45AM - 2:30PM
On Own for Lunch


Tuesday, December 06 | 11:45AM - 1:00PM
Poster Setup
Room: Mesa C


Tuesday, December 06 | 1:00PM - 10:00PM
Poster Viewing
Room: Mesa C


Tuesday, December 06 | 2:30PM - 3:30PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II
Room: Mesa A-B

Speaker 1 of 5
* Lisa E. Hensley, NIAID, National Institutes of Health, USA

Tuesday, December 06 | 2:30PM - 3:30PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II
Room: Mesa A-B

Speaker 2 of 5
Roberto Aiolfi, The Scripps Research Institute, USA
Defective Platelet Thromboxane A2 Signaling and Serotonin Release in the Pathogenesis of Bleeding during Viral Infection

Tuesday, December 06 | 2:30PM - 3:30PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II
Room: Mesa A-B

Speaker 3 of 5
Anne-Marie Connolly-Andersen, Umeå University, Sweden
Pulmonary Endothelial Glycocalyx Degradation in Hantavirus Infection

Tuesday, December 06 | 2:30PM - 3:30PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II
Room: Mesa A-B

Speaker 4 of 5
Ashley St. John, Duke-NUS Medical School, Singapore
Dengue Virus-Elicited Tryptase Breaks Tight Junctions to Induce Endothelial Permeability and Shock

Tuesday, December 06 | 2:30PM - 3:30PM
Workshop 2A: Endothelial Dysfunction and Coagulopathy II
Room: Mesa A-B

Speaker 5 of 5
Brian Martin Sullivan, The Scripps Research Institute, USA
Linking Platelet Dysfunction to Cytotoxic T Cell Responses during Lethal Viral Hemorrhagic Fever Infection

Tuesday, December 06 | 3:30PM - 4:30PM
Workshop 2B: Clinical and Immunologic Findings during Lassa
Infection
Room: Mesa A-B

Speaker 1 of 4
* Colleen S. Kraft, Emory University, USA

Tuesday, December 06 | 3:30PM - 4:30PM
Workshop 2B: Clinical and Immunologic Findings during Lassa
Infection
Room: Mesa A-B

Speaker 2 of 4
Aneesh K. Mehta, Emory University, USA
Novel Insights into the Clinical Care of Lassa Disease

Tuesday, December 06 | 3:30PM - 4:30PM
Workshop 2B: Clinical and Immunologic Findings during Lassa
Infection
Room: Mesa A-B

Speaker 3 of 4
Anita K. McElroy, Emory University, USA
The Human Innate and Adaptive Immune Response to Lassa Virus Infection: A Case Study

Tuesday, December 06 | 3:30PM - 4:30PM
Workshop 2B: Clinical and Immunologic Findings during Lassa
Infection
Room: Mesa A-B

Speaker 4 of 4
Lisa Oestereich, Heinrich Pette Institute, Germany
Human Immune Responses to Lassa Infection in Nigeria

Tuesday, December 06 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Tuesday, December 06 | 5:00PM - 7:00PM
Diagnostics
Room: Mesa A-B

Speaker 1 of 4
* Jonathan S. Towner, Centers for Disease Control and Prevention, USA
Filovirus Replication in Naturally and Experimentally Infected Bats

Tuesday, December 06 | 5:00PM - 7:00PM
Diagnostics
Room: Mesa A-B

Speaker 2 of 4
Stephan Günther, Bernhard-Nocht-Institut für Tropenmedizin, Germany
Diagnosis of Ebola Virus Disease during the Outbreak in West Africa

Tuesday, December 06 | 5:00PM - 7:00PM
Diagnostics
Room: Mesa A-B

Speaker 3 of 4
John H. Connor, Boston University School of Medicine, USA
Short Talk: Real-Time Visualization of Individual Hemorrhagic Fever Virions in Solution

Tuesday, December 06 | 5:00PM - 7:00PM
Diagnostics
Room: Mesa A-B

Speaker 4 of 4
Frederick Holtsberg, Integrated Biotherapeutics, USA
Short Talk

Tuesday, December 06 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pecos/Canyon
No registration fees are used to fund alcohol served at this function.

Tuesday, December 06 | 7:30PM - 10:00PM
Poster Session 2
Room: Mesa C


Wednesday, December 07 | 7:30AM - 8:30AM
Breakfast
Room: Pecos/Canyon


Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 1 of 8
* Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 2 of 8
Michael Egan, Profectus Biosciences, USA
Filovirus rVSV Vaccines

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 3 of 8
Sheri Dubey, Merck & Co., Inc., USA
Clinical Development of a Recombinant Ebola Vaccine in the Midst of an Unprecedented Outbreak

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B


Coffee Break

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 5 of 8
Heinz Feldmann, Rocky Mountain Laboratories, USA
Lassa rVSV Vaccines

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 6 of 8
Andrea Marzi, NIAID, National Institutes of Health, USA
Short Talk: Efficacy of VSV-EBOV Post-Exposure Treatment in Rhesus Macaques Infected with EBOV-Makona

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 7 of 8
Farshad Guirakhoo, GeoVax, Inc., USA
Short Talk: MVA-VLP Platform for Development of a Single Dose Tetravalent Vaccine against Hemorrhagic Fever Viruses

Wednesday, December 07 | 8:30AM - 11:30AM
Vaccines I
Room: Mesa A-B

Speaker 8 of 8
Igor Lukashevich, University of Louisville, USA
Short Talk: Reassortant ML29 Vaccine Platform to Control Lassa Fever in West Africa

Wednesday, December 07 | 11:30AM - 5:00PM
On Own for Lunch


Wednesday, December 07 | 11:30AM - 1:00PM
Poster Setup
Room: Mesa C


Wednesday, December 07 | 1:00PM - 10:00PM
Poster Viewing
Room: Mesa C


Wednesday, December 07 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Wednesday, December 07 | 5:00PM - 7:00PM
Vaccines II
Room: Mesa A-B

Speaker 1 of 5
* Heinz Feldmann, Rocky Mountain Laboratories, USA

Wednesday, December 07 | 5:00PM - 7:00PM
Vaccines II
Room: Mesa A-B

Speaker 2 of 5
Anna P. Durbin, Johns Hopkins Bloomberg School of Public Health, USA
The Live Attenuated Dengue Vaccines TV003 and TV005 Completely Protect Against DENV-2 Infection in a Controlled Dengue Human Challenge Model


Wednesday, December 07 | 5:00PM - 7:00PM
Vaccines II
Room: Mesa A-B

Speaker 3 of 5
Shinji Makino, University of Texas Medical Branch, USA
Development of a Single-Cycle Replicable Rift Valley Fever Virus Vaccine

Wednesday, December 07 | 5:00PM - 7:00PM
Vaccines II
Room: Mesa A-B

Speaker 4 of 5
Connie S. Schmaljohn, US Army Medical Research Institute of Infectious Disease, USA
Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome (HFRS)

Wednesday, December 07 | 5:00PM - 7:00PM
Vaccines II
Room: Mesa A-B

Speaker 5 of 5
Courtney Brooke Woolsey, University of Texas Medical Branch, USA
Short Talk: A Recombinant Vesicular Stomatitis Virus-Based Vaccine Mediates Post-Exposure Protection against Marburg Virus Angola in Rhesus Macaques

Wednesday, December 07 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pecos/Canyon
No registration fees are used to fund alcohol served at this function.

Wednesday, December 07 | 7:30PM - 10:00PM
Poster Session 3
Room: Mesa C


Thursday, December 08 | 7:30AM - 8:30AM
Breakfast
Room: Pecos/Canyon


Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 1 of 9
* Andrea Marzi, NIAID, National Institutes of Health, USA

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 2 of 9
Larry Zeitlin, Mapp Biopharmaceutical, Inc., USA
Junin and Filovirus mAb Therapeutics

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 3 of 9
Thomas W. Geisbert, University of Texas Medical Branch, USA
Filovirus siRNA Therapeutics

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B


Coffee Break

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 5 of 9
Luis M. Branco, Zalgen Labs, LLC, USA
Lassa Virus Human Monoclonal Antibody Therapeutics

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 6 of 9
Eric Bergeron, Centers for Disease Control and Prevention, USA
Short Talk: Antiviral Activity and Mechanism of Action of Site-1 Protease (S1P) Inhibitor on Crimean-Congo Hemorrhagic Fever Virus

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 7 of 9
Zachary Bornholdt, Mapp Biopharmaceutical, USA
The Structure-Based Design of a Pan-ebolavirus Immunotherapeutic Cocktail

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 8 of 9
Anna Z. Wec, Adimab LLC, USA
Short Talk: Bispecific Antibodies Targeting the Intracellular Virus-Receptor Interaction Provide Broad in vivo Protection Against Ebolaviruses

Thursday, December 08 | 8:30AM - 11:45AM
Therapeutics I
Room: Mesa A-B

Speaker 9 of 9
Bronwyn M. Gunn, Massachusetts General Hospital, USA
Short Talk: Antibody Fc-Effector Functionality Predicts Monoclonal Antibody-Mediated Post-Exposure Protection against Ebola Virus Challenge

Thursday, December 08 | 11:45AM - 5:00PM
On Own for Lunch


Thursday, December 08 | 4:30PM - 5:00PM
Coffee Available
Room: Promenade


Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 1 of 6
* Chad E. Mire, Galveston National Laboratory, USA

Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 2 of 6
Brian Gowen, Utah State University, USA
Prospects for Treatment of Severe Arenavirus and Bunyavirus Infections

Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 3 of 6
M. Javad Aman, Integrated Biotherapeutics, Inc., USA
Short Talk: Cross-Protection Against Ebolaviruses with Vaccine Elicited Broadly Neutralizing Monoclonal Antibody Cocktails: Evidence for Cooperative Neutralization

Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 4 of 6
Travis K. Warren, US Army Medical Research Institute of Infectious Diseases, USA
In vivo Efficacy of BCX4430 Against Ebola Virus

Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 5 of 6
John Misasi, NIAID, National Institutes of Health, USA
Protective Monotherapy Against Ebola Infection: Structure and Molecular Basis of Potent Neutralization

Thursday, December 08 | 5:00PM - 7:15PM
Therapeutics II
Room: Mesa A-B

Speaker 6 of 6
Ami Patel, Wistar Institute, USA
Short Talk: DNA-Delivery of Monoclonal Antibodies (DMAbs) as an Alternative, in vivo mAb Delivery Platform against Ebola Virus Infection

Thursday, December 08 | 8:00PM - 9:00PM
Social Hour with Lite Bites
Room: Promenade/Mesa Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, December 08 | 8:00PM - 11:00PM
Entertainment
Room: Mesa Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, December 08 | 9:00PM - 11:00PM
Cash Bar
Room: Mesa Ballroom


Friday, December 09 | 10:25AM - 10:25AM
Departure


*Session Chair.